GSK plc, the global biopharma company listed on the London Stock Exchange, has disclosed that seven senior executives and one person closely associated with a director acquired ordinary shares on 10 November 2026 under the company's Share Reward Plan at a price of £19.3453 per share. A further executive, Maya Martinez-Davis, President, US, separately acquired notional American Depositary Shares within her GSK Executive Supplemental Savings Plan account on 9 November 2026 on the New York Stock Exchange. The notifications, published on 12 November 2026, are required disclosures under UK market transparency rules and cover both partnership shares and matching shares awarded through the plan.

Key Points

  • GSK plc (GSK) — global biopharma company registered in England and Wales
  • Seven PDMRs each acquired 12 ordinary shares (6 partnership, 6 matching) at £19.3453; Company Secretary Victoria Whyte acquired 14 shares (7 partnership, 7 matching) at the same price on 10 November 2026
  • Maya Martinez-Davis acquired 9.264 notional ADS at $51.5400 each on 9 November 2026 via the GSK Executive Supplemental Savings Plan on the New York Stock Exchange
  • Investors may watch whether further routine Share Reward Plan disclosures follow in coming months

GSK Share Reward Plan Acquisitions by Seven Senior Executives on 10 November 2026

The announcement states that Lynn Baxter (CEO, ViiV Healthcare and President, Global Health), Julie Brown (Chief Financial Officer), David Redfern (President, Corporate Development), Regis Simard (President, Global Supply Chain), James Strenner (President, Europe), Philip Thomson (President, Global Affairs), and Neil Falkingham (a person closely associated with Lynn Baxter) each acquired 12 ordinary shares of 31¼ pence each at £19.3453 per share on 10 November 2026 on the London Stock Exchange. Each acquisition comprised six partnership shares and six matching shares awarded under GSK's Share Reward Plan, with the ISIN for the ordinary shares recorded as GB00BN7SWP63.

Victoria Whyte and Maya Martinez-Davis Complete Separate Plan Transactions

Victoria Whyte, SVP and Company Secretary, acquired 14 ordinary shares — seven partnership and seven matching — at £19.3453 on 10 November 2026 on the London Stock Exchange, slightly more than her fellow plan participants. Separately, Maya Martinez-Davis, President, US, acquired 9.264 notional American Depositary Shares at $51.5400 each on 9 November 2026 through her GSK Executive Supplemental Savings Plan account on the New York Stock Exchange. The ADS carry ISIN US37733W2044. The announcement does not detail the total sterling value of Ms Martinez-Davis's transaction beyond the disclosed price and volume.

Routine PDMR Disclosures Reflect GSK's Broad Executive Participation in Share Plans

The breadth of executives named across these notifications — spanning finance, supply chain, regional leadership, corporate development, global affairs, and the ViiV Healthcare HIV-focused unit — illustrates the structured, company-wide nature of GSK's Share Reward Plan. Such plans typically align executive interests with long-term shareholder value, though the small volumes involved in routine plan acquisitions are not in themselves indicative of any change in corporate strategy or financial outlook. GSK describes itself as a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together, with its registered office at 79 New Oxford Street, London.